Open Access
Issue
J Extra Corpor Technol
Volume 49, Number 4, December 2017
Page(s) 273 - 282
DOI https://doi.org/10.1051/ject/201749273
Published online 15 December 2017
  1. Carson JL, Carless PA, Hebert PC Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2012;4:CD002042. [PubMed] [Google Scholar]
  2. Likosky DS, Dickinson TA, Paugh TA Blood conservation–A team sport. J Extra Corpor Technol. 2016;48:99–104. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  3. Yang JC, Sun Y, Xu CX, et al. Correlation between red blood cell transfusion volume and mortality in patients with massive blood transfusion: A large multicenter retrospective study. Exp Ther Med. 2015;9:137–42. [CrossRef] [PubMed] [Google Scholar]
  4. Surgenor SD, DeFoe GR, Fillinger MP, et al. Intraoperative red blood cell transfusion during coronary artery bypass graft surgery increases the risk of postoperative low-output heart failure. Circulation. 2006;114:I43–8. [CrossRef] [PubMed] [Google Scholar]
  5. Surgenor SD, Kramer RS, Olmstead EM, et al. The association of perioperative red blood cell transfusions and decreased long-term survival after cardiac surgery. Anesth Analg. 2009;108:1741–6. [CrossRef] [PubMed] [Google Scholar]
  6. Moiskowitz DM, McCullough JN, Shander A, et al. The impact of blood conservation on outcomes in cardiac surgery: Is it safe and effective? Ann Thorac Surg. 2010;90:451–9. [CrossRef] [PubMed] [Google Scholar]
  7. Bagge L, Thelin S, Hultman J, et al. Heparin-coated CPB-sets increase biocompatibility and reduce endothelial cell damage in pigs. J Cardiothorac Anesth. 1989;3(Suppl 1):84. [PubMed] [Google Scholar]
  8. Nilsson L, Storm KE, Thelin S, et al. Hepa-rin-coated equipment reduces complement activation during cardiopulmonary bypass in the pig. Artif Organs. 1990;14:46–8. [Google Scholar]
  9. Thelin S, Bagge L, Hultman J, et al. Heparin-coated cardiopulmonary bypass circuits reduce blood cell trauma. Experiments in the pig. Eur J Cardiothorac Surg. 1991;5:486–91. [CrossRef] [PubMed] [Google Scholar]
  10. Belboul A, al-Khaja N Does heparin coating improve biocompatibility? A study on complement, blood cells and postoperative morbidity during cardiac surgery. Perfusion. 1997;12:385–91. [CrossRef] [PubMed] [Google Scholar]
  11. Palanzo DA, Zarro DL, Manley NJ, et al. Effect of Carmeda BioActive Surface coating versus Trillium Biopassive Surface coating of the oxygenator on circulating platelet count drop during cardiopulmonary bypass. Perfusion. 2001;16:279–83. [CrossRef] [PubMed] [Google Scholar]
  12. Flom-Halvorsen HI, Ovrum E, Brosstad F, et al. Effects of two differently heparin-coated extracorporeal circuits on markers for brain and myocardial dysfunction. Perfusion. 2002;17:339–45. [CrossRef] [PubMed] [Google Scholar]
  13. Ferraris VA, Brown JR, Despotis J, et al. Update to the Society of Thoracic Surgeons & Society of CV Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg. 2011;91:944–82. [CrossRef] [PubMed] [Google Scholar]
  14. Dunning J, Versteegh M, Fabbri A, et al. Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg. 2008;34:73–92. [CrossRef] [PubMed] [Google Scholar]
  15. Giglia T, Massicotte MP, Tweddell JS, et al. Prevention and treatment of thrombosis in pediatric and CHD: A scientific statement from the American Heart Association. Circulation. 2013;128:2622–703. [CrossRef] [PubMed] [Google Scholar]
  16. Despotis GJ, Joist JH, Hogue CWJr, et al. Impact of heparin concentration and activated clotting time monitoring on blood conservation. J Thorac Cardiovasc Surg. 1995;110:46–54. [CrossRef] [PubMed] [Google Scholar]
  17. Raymond PD, Ray MJ, Callen SN, et al. Heparin monitoring during cardiac surgery. Part 1: Validation of whole-blood heparin concentration and activated clotting time. Perfusion. 2003;18:269–76. [CrossRef] [PubMed] [Google Scholar]
  18. Raymond PD, Ray MJ, Callen SN, et al. Heparin monitoring during cardiac surgery. Part 2: Calculating the overestimation of heparin by the activated clotting time. Perfusion. 2003;18:277–81. [CrossRef] [PubMed] [Google Scholar]
  19. Santrach PJ Devices for monitoring heparin and protamine in the operating room. Semin Cardiothorac Vasc Anesth. 2003;7:379–85. [CrossRef] [Google Scholar]
  20. Yamanishi H, Watanabe S, Hayashi K, et al. A clinical evaluation of the Hepcon/HMS: A new device of monitoring hemostasis management during cardio-pulmonary bypass. Kyobu Geka. 1997;50:459–62. [PubMed] [Google Scholar]
  21. Noui N, Zogheib E, Walczak K, et al. Anticoagulation monitoring during extracorporeal circulation with the Hepcon/HMS device. Perfusion. 2012;27:214–20. [CrossRef] [PubMed] [Google Scholar]
  22. Garvin S, FitzGerald DC, Despotis G, et al. Heparin concentration-based anticoagulation for cardiac surgery fails to reliably predict heparin bolus dose requirements. Anesth Analg. 2010;111:849–55. [CrossRef] [PubMed] [Google Scholar]
  23. Zecchillo F Hemolysis In Vivo on Fusion. Rome, Italy: Options & Outcomes; 2014. [Google Scholar]
  24. Leverett LB, Hellums JD, Alfrey CP, et al. Red blood cell damage by shear stress. Biophys J. 1972;12:257–73. [CrossRef] [PubMed] [Google Scholar]
  25. Schon J, Serien V, Hanke T, et al. Cerebral oxygen saturation monitoring in on-pump cardiac surgery–A 1-year experience. Appl Cardiopulm Pathophysiol. 2009;13:243–52. [Google Scholar]
  26. Monhandas BS, Jagadeesh AM, Vikram SB Impact of monitoring cerebral oxygen saturation on the outcome of patients undergoing open heart surgery. Ann Card Anaesth. 2013;16:102–6. [CrossRef] [PubMed] [Google Scholar]
  27. Colak Z, Borojevic M, Bogovic A, et al. Influence of intraoperative cerebral oximetry monitoring on neurocognitive function after coronary artery bypass surgery: A randomized, prospective study. Eur J Cardiothorac Surg. 2015;47:447–54. [CrossRef] [PubMed] [Google Scholar]
  28. Alta Bates Summit Medical Center. Total Hospitalization cost per procedure. Data on file with Pathology Department, Alta Bates Summit Medical Center. Oakland, CA: Alta Bates Summit Medical Center; 2014–2017. [Google Scholar]
  29. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 update: A report from the American Heart Association. Circulation. 2016;133:E38–360. [PubMed] [Google Scholar]
  30. Medtronic. Hemodynamic Studies. Minneapolis, MN: Medtronic, Inc.; 2014. [Google Scholar]
  31. Medtronic. Medtronic Internal Bench Top Testing Performed In-Vitro Validation Testing. Unpublished Raw Data. Minneapolis, MN: Medtronic, Inc.; 2011. [Google Scholar]
  32. Adkins JR, Hardy JD Sodium heparin neutralization and the anticoagulant effects of protamine sulfate. Arch Surg. 1967;94:175. [CrossRef] [PubMed] [Google Scholar]
  33. Shanberge JN, Fukui H Studies on the anti-coagulant action of heparin, protamine, and poly-brene in the activation of factor IX. J Lab Clin Med. 1967;69:927. [PubMed] [Google Scholar]
  34. Ainle FN, Preston RJ, Jenkins PV, et al. Protamine sulfate down-regulates thrombin generation by inhibiting factor V activation. Blood. 2009;114:1658–65. [CrossRef] [PubMed] [Google Scholar]
  35. Chu A Protamine inhibits tissue factor-initiated extrinsic coagulation. Br J Haematol. 2001;115:392–9. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.